Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cediranib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 11/20 | 0.87 |
| ▸ | FLT1 known ✓ | P17948 | 5/20 | 0.87 |
| ▸ | FLT4 known ✓ | P35916 | 5/20 | 0.87 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.87 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.87 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.87 |
| ▸ | RET | P07949 | 4/20 | 0.87 |
| ▸ | PLK4 | O00444 | 1/20 | 0.87 |
| ▸ | GAK | O14976 | 1/20 | 0.87 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.87 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.87 |
| ▸ | ERN1 | O75460 | 1/20 | 0.87 |
| ▸ | STK10 | O94804 | 1/20 | 0.87 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.87 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.87 |
| ▸ | ABL1 | P00519 | 1/20 | 0.87 |
| ▸ | EGFR | P00533 | 1/20 | 0.87 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.87 |
| ▸ | LCK | P06239 | 1/20 | 0.87 |
| ▸ | FYN | P06241 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cediranib SCHEMBL23924949 | 1.00 | KDR (0.87) | KDRFLT1FLT4RETPLK4 | |
| Cediranib SCHEMBL1218427 | 1.00 | KDR (0.87) | KDRFLT1FLT4RETPLK4 | |
| Cediranib SCHEMBL29351942 | 1.00 | KDR (0.87) | KDRFLT1FLT4RETPLK4 | |
| Cediranib SCHEMBL63147 | 0.93 | KDR (1.00) | KDRFLT1FLT4RETPLK4 | |
| Cediranib SCHEMBL29383181 | 0.93 | KDR (1.00) | KDRFLT1FLT4RETPLK4 | |
| Cediranib SCHEMBL29351458 | 0.93 | KDR (1.00) | KDRFLT1FLT4RETPLK4 | |
| Cediranib SCHEMBL29368143 | 0.93 | KDR (1.00) | KDRFLT1FLT4RETPLK4 | |
| SCHEMBL1685423 | 0.92 | ABCB11 (1.00) | KDRFLT1FLT4RETPLK4 | |
| SCHEMBL1401646 | 0.88 | KDR (0.81) | KDRFLT1FLT4RETPLK4 | |
| SCHEMBL297569 | 0.88 | KDR (0.81) | KDRFLT1FLT4RETPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170913-A1 | MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT | ASTRAZENECA AB (SE) | 2018-06-21 | — | — | US | claimed |
| US-9890140-B2 | Maleate salts of a quinazoline derivative useful as an antiangiogenic agent | ASTRAZENECA AB (SE) | 2018-02-13 | — | — | US | claimed |
| US-9556151-B2 | Maleate salts of a quinazoline derivative useful as an antiangiogenic agent | ASTRAZENECA AB (SE) | 2017-01-31 | — | — | US | claimed |
| EP-1699782-B1 | MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT | ASTRAZENECA AB (SE) | 2010-06-23 | — | — | EP | claimed |
| US-20180170913-A1 | MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT | ASTRAZENECA AB (SE) | 2018-06-21 | — | — | US | disclosed |
| US-9890140-B2 | Maleate salts of a quinazoline derivative useful as an antiangiogenic agent | ASTRAZENECA AB (SE) | 2018-02-13 | — | — | US | disclosed |
| US-9556151-B2 | Maleate salts of a quinazoline derivative useful as an antiangiogenic agent | ASTRAZENECA AB (SE) | 2017-01-31 | — | — | US | disclosed |
| US-20150025091-A1 | Maleate Salts of a Quinazoline Derivative Useful as an Antiangiogenic Agent | ASTRAZENECA AB (SE) | 2015-01-22 | — | — | US | disclosed |
| US-8859570-B2 | Maleate salts of a quinazoline derivative useful as an antiangiogenic agent | ASTRAZENECA AB (SE) | 2014-10-14 | — | — | US | disclosed |
| US-8754240-B2 | Process for the manufacture of 4-fluoro-2-methyl-1H-indol-5-ol | ASTRAZENECA AB (SE) | 2014-06-17 | — | — | US | disclosed |
| EP-2540705-A2 | Process for preparing indol-5-oxy-quinazoline derivatives and intermediates | AstraZeneca AB (Publ) (SE) | 2013-01-02 | — | — | EP | disclosed |
| EP-2540706-A2 | PROCESS FOR PREPARING INDOL-5-OXY-QUINAZOLINE DERIVATIVES AND INTERMEDIATES | AstraZeneca AB (Publ) (SE) | 2013-01-02 | — | — | EP | disclosed |
| US-7851623-B2 | Chemical process | ASTRAZENECA AB (SE) | 2010-12-14 | — | — | US | disclosed |
| US-20100298357-A1 | MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-1699782-B1 | MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT | ASTRAZENECA AB (SE) | 2010-06-23 | — | — | EP | disclosed |
| EP-2129657-A2 | PROCESS FOR PREPARING INDOL-5-OXY-QUINAZOLINE DERIVATIVES AND INTERMEDIATES | AstraZeneca AB (SE) | 2009-12-09 | — | — | EP | disclosed |
| WO-2009104019-A1 | COMBINATION THERAPY 238 | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | WO | disclosed |
| US-20080221322-A1 | CHEMICAL PROCESS | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008053221-A2 | PROCESS FOR PREPARING INDOL- 5 -OXY- QUINAZOLINE DERIVATIVES AND INTERMEDIATES | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
| US-20070129387-A1 | Maleate salts of a quinazoline derivative useful as an antiangiogenic agent | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170913-A1 | MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT | FLT1, TEK, FLT4 | KDR 4/4885FLT1 1/4885FLT4 3/4885 |
| US-20100298357-A1 | MALEATE SALTS OF A QUINAZOLINE DERIVATIVE USEFUL AS AN ANTIANGIOGENIC AGENT | FLT1, TEK, FLT4 | KDR 4/4885FLT1 1/4885FLT4 3/4885 |
| US-20150025091-A1 | Maleate Salts of a Quinazoline Derivative Useful as an Antiangiogenic Agent | FLT1, TEK, FLT4 | KDR 4/4885FLT1 1/4885FLT4 3/4885 |
| US-20070129387-A1 | Maleate salts of a quinazoline derivative useful as an antiangiogenic agent | FLT1, TEK, FLT4 | KDR 4/4885FLT1 1/4885FLT4 3/4885 |
| US-20080221322-A1 | CHEMICAL PROCESS | CYP3A5, CYP3A4, CYP3A7 | KDR 3684/4885FLT1 3138/4885FLT4 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.